Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Excipients list used in dexamethasone creams?
Antiox mebendazole price?
Are there specific stretches to avoid while on lipitor?
When did risperdal constas patent expire published article?
Pramlintide fda approval date?

Inclisiran generic?

See the DrugPatentWatch profile for Inclisiran

Inclisiran (generic status)

Item Information
Brand name Leqvio (by Alnylam Pharmaceuticals)
Drug class Small‑interfering RNA (siRNA) that targets PCSK9 mRNA to reduce LDL‑cholesterol.
FDA approval Approved in the U.S. in 2021 (and in many other jurisdictions).
Generic availability As of now (2026‑08) the FDA has not approved a generic version of inclisiran. The product remains available only under its brand name, Leqvio.
Why no generic yet? Generic approval requires the sponsor to submit a Abbreviated New Drug Application (ANDA) demonstrating bioequivalence to the brand product. For biologics‑derived drugs such as siRNA, the approval process is complex and often the original company holds exclusive rights for several years.
When might a generic appear? Potentially after the exclusivity period ends, or if a third‑party manufacturer files an ANDA and successfully demonstrates equivalence. This can take several years, so a precise timeline is uncertain.
Other markets Some countries, especially in Europe, have approved inclisiran under its brand name but no generic versions are currently listed in the European Medicines Agency (EMA) database.
Cost considerations Without a generic, the drug remains relatively expensive (roughly $11,000–$13,000 per year in the U.S.). Insurance coverage, patient assistance programs, and negotiated discounts are common ways to manage the cost.

What does this mean for patients and prescribers?

  • Prescription: If you’re a patient needing inclisiran, you’ll be prescribed Leqvio, and your pharmacy will dispense the brand product.
  • Insurance & copay: Most insurers cover inclisiran, often with a prior‑authorization requirement.
  • Future generics: Once a generic is approved, it is typically priced lower than the brand. Until that happens, the brand remains the sole option.

Bottom line

  • No generic inclisiran is currently approved in the U.S. or EU.
  • The drug is available only as Leqvio, with its associated cost structure.
  • Keep an eye on FDA announcements—generic approval could happen in the next few years, but the exact date isn’t set.

If you have questions about coverage, insurance options, or whether you’re eligible for a patient assistance program, it’s best to talk directly with your prescriber or pharmacist.



Other Questions About Inclisiran :

Whe does nce expire for inclisiran in us? Inclisiran approval date? Inclisiran patentschutz? Inclisiran novartis patent? Inclisiran sale price? Inclisiran patent expiration? Inclisiran launch date?